Fatigue News and Research

RSS

Growing rates of syphilis among gay and bisexual men

Armed with more than a decade's worth of statistics, researchers are sounding a new alarm about growing rates of syphilis among gay and bisexual men.

27 Apr 2007

Interactive exercises for repetitive stress injuries

Desk-Trainer Ltd., specialists in the development of the successful five minute interactive exercise programs, announces the launch of a new Swedish sub-site with 10 first exercises translated into Swedish designed to protect against pain and injury resulting from Repetitive Stress Injuries (RSI) or other physical activities. During the first 4 weeks Desk-Trainer will offer 5 exercises in Swedish FREE.

26 Apr 2007

Long-term effects of a disaster on physical and psychological health

The long-term effects of a disaster on physical and psychological health are the focus of a new study of rescue workers who provided assistance after the explosion of a fireworks depot in the Netherlands in May 2000.

24 Apr 2007

Pediatric multiple sclerosis and related disorders

Pediatric Multiple Sclerosis and Related Disorders has just been published by the International Pediatric MS Study Group as a supplement to the journal Neurology.

24 Apr 2007

Potential therapeutic target for multiple sclerosis

Oregon Health & Science University neuroscientists are eyeing a protein as a potential therapeutic target for multiple sclerosis because de-activating it protects nerve fibers from damage.

24 Apr 2007

Schering-Plough announces ZETIA spproved in Japan

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine.

20 Apr 2007

Talk beyond pain: Understanding diabetic nerve pain

Results from a new survey of more than 600 physicians who treat diabetic peripheral neuropathic pain, or diabetic nerve pain, reveal that nearly all (97 percent) believe that the condition is often misdiagnosed.

20 Apr 2007

Autonomy Laparo-angle instrumentation from Cambridge Endo

Cambridge Endo, a Massachusetts-based medical device company, has announced the development of the first full-line of fully articulating hand-held instruments for laparoscopic surgeons: Autonomy Laparo-Angle Instrumentation.

20 Apr 2007

Chinese herbs may help women with breast cancer

Using Chinese herbs either alone or in conjunction with chemotherapy may help protect a breast cancer patient’s bone marrow and immune system, as well as improving the woman’s overall quality of life.

19 Apr 2007

Collagen injected meatballs!

Injecting meatballs with collagen can help the meat to retain the important nutrients iodine and thiamine, a new study by researchers from the Agricultural University of Poznan in Poland shows.

18 Apr 2007

OncoGenex Technologies announces data from a Phase II clinical trial of OGX-011

The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.

18 Apr 2007

Lactate instead of glucose after traumatic brain injury

The chemical lactate has gotten a bad rap. Conventional wisdom considered it to be little more than the bane of runners and other athletes, causing stiff muscles and fatigue, and the "sour" in sour milk. It turns out that view may have been too narrow.

15 Apr 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007

Increase in shift-work among junior doctors could have a detrimental effect on the NHS

Changes in working practice and the introduction of the EWTD have led to a much needed reduction in the number of hours junior doctors work. However it has also meant an increase in shift-working. Most full shift rotas require junior doctors to work seven consecutive, 13 hour night shifts, a practice the Royal College of Physicians recently recommended should be avoided.

15 Apr 2007

Physical, emotional burden of breast cancer lingers for older survivors

Surviving breast cancer is both a physical and an emotional ordeal, but the consensus among researchers is that life generally returns to normal for most women within two years of completing treatment.

7 Apr 2007

Targeted therapies improve colon cancer survival rates

People diagnosed with advanced colorectal cancer that has spread to distant organs, such as White House spokesman Tony Snow, are much more likely to survive today than even just a few years ago, due to the recent and continued emergence of improved therapies, say cancer experts.

3 Apr 2007

Advances in clinical cardiology

Three studies being presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La., highlight the breadth of research propelling advances in clinical cardiology.

3 Apr 2007

Withdrawal of Pergolide products

The U.S. Food and Drug Administration (FDA) today announced that manufacturers of pergolide drug products, which are used to treat Parkinson's disease, will voluntarily remove these drugs from the market because of the risk of serious damage to patients' heart valves.

29 Mar 2007

FDA approves Soliris (eculizumab), first treatment for paroxysmal nocturnal hemoglobinuria

The U.S. Food and Drug Administration (FDA) has approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death.

19 Mar 2007

Tykerb (lapatinib) - new anti-cancer treatment approved

The Food and Drug Administration (FDA) has approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).

14 Mar 2007